TC BioPharm Limited

Developing a cancer therapy with demonstrable evidence of clinical benefit. Formulated to treat a variety of tumour types. Pipeline = HIV and viral infections.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Edinburgh, United Kingdom
  • Currency GBP
  • Founded July 2013
  • Employees 15
  • Website http://tcbiopharm.com

Company Summary

TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders including cancer and severe viral infections such as HIV.
Commencing phase II/III studies in melanoma patients mid-2105; the company aims to IPO late 2016 to support EU/US marketing authorization.

Team

  • Angela Scott
    Operations Director

    Angela Scott has a BSc in Life Sciences and over 30 years’ hands on experience in stem cell research and cutting edge cell therapy. Originally part of the ground-breaking team that cloned ‘Dolly the sheep’; Angela played a major role at AngelBio in establishing its reputation as a centre of excellence in the field of cellular therapies. Angela has contributed to the transition of several cell therapy products from the bench to bedside.

  • Michael Leek
    Chief Executive

    Jointly responsible for moving Intercytex from a pre-clinical research company to an AIM-listed biotech with several cell therapy products in the clinic. Michael is currently CEO of TC BioPharm, and has previously worked as CEO of an orthobiologicals company, and with a clinical team developing an autologous infusion of stem cells to initiate regeneration of new hepatic tissue.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free